{"id":5246,"date":"2025-03-31T10:00:36","date_gmt":"2025-03-31T10:00:36","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?post_type=biomarker-solution&p=5246"},"modified":"2025-06-03T08:14:30","modified_gmt":"2025-06-03T08:14:30","slug":"crohns-disease","status":"publish","type":"biomarker-solution","link":"https:\/\/www.nordicbioscience.com\/biomarker-solution\/gastrointestinal-diseases\/crohns-disease\/","title":{"rendered":"Crohn’s Disease"},"content":{"rendered":"
\n \n
\n
\n
\n
\n

NordicIBDTrace\u2122<\/h2>\n \n\n <\/div>\n
\n

Crohn’s disease is characterized by chronic inflammation leading to progressive mucosal destruction and scar tissue formation through remodeling of the extracellular matrix (ECM).<\/p>\n

The\u00a0Nordic\u00a0IBDTrace\u2122\u00a0biomarker panel quantifies the degree of inflammation (nordicCPa9-HNE\u2122<\/a>, <\/i>VICM<\/a>), mucosal damage (e.g.,\u00a0C3M<\/a>, C4M<\/a>, C7M<\/a>), and fibrotic processes (e.g., nordicPRO-C3\u2122<\/a>, nordicCTX-III\u2122<\/a>, nordicPRO-C6\u2122<\/a>) by measuring fragments of protease-mediated degradation of mucosal proteins released into the bloodstream.<\/p>\n

The\u00a0Nordic\u00a0IBDTrace\u2122\u00a0biomarker panel provides a blood-based approach to refine drug development strategies and accelerate the path to effective treatments. By offering mechanistic insights into ECM remodeling and immune cell activity,\u00a0IBDTrace\u2122\u00a0biomarkers improve patient stratification, support internal decision-making, and enhance overall efficiency in clinical trials.<\/p>\n

Additionally, these biomarkers can help elucidate the mode of action of investigational therapies while serving as a non-invasive alternative to frequent procedures like endoscopy.<\/p>\n <\/div>\n <\/div>\n

\n \n Browse nordicIBDTrace\u2122 \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

Mucosal damage and immune cell activity <\/h2>\n \n\n <\/div>\n
\n

Studies have shown that ECM remodeling precedes clinically apparent inflammation \u2013 therefore, biomarkers of mucosal damage and immune cell activity reflect intestinal barrier integrity, providing a comprehensive understanding of the pathological state of the tissue.<\/p>\n

By capturing these pathological changes, such biomarkers offer a valuable approach to accurately prognosticate disease course, serve as indicators of pharmacodynamic response, and monitor or predict response to therapeutics, supporting both clinical trial optimization and internal decision-making.<\/p>\n

Biomarkers of immune cell activity (nordicCPa9-HNE\u2122<\/a>, VICM<\/a>) and mucosal damage, such as the MMP-mediated degradation of type III, IV, and VII collagen (C3M<\/a>, C4M<\/a>, C7M<\/a>), correlate with both clinical and endoscopic disease activity in ulcerative colitis, as assessed by UCEIS and the total Mayo score. Additionally, the ratio of type III collagen degradation to formation (C3M\/nordicPRO-C3\u2122<\/a>) provides further insight into ECM turnover, offering a more comprehensive assessment of tissue remodeling.<\/p>\n

These biomarkers provide a non-invasive tool for monitoring disease progression and may support patient subgrouping, aiding in trial optimization strategies.<\/p>\n <\/div>\n

\n

Browse our biomarker panels<\/h3>\n